Ceftezole is an α-Glucosidase inhibitor (IC50: 2.1 μM; Ki: 0.578 μM).

In vivo streptozotocin-induced mouse model, blood glucose levels are decreased by 30% 20 min after Ceftezole treatment (10 mg/kg/day). Expression levels of GSK-3, peroxisome proliferator-activated receptor-γ, and uncoupling protein-3 mRNA are also slightly decreased compared to controls following Ceftezole treatment.

65307-12-2

C16H15N5O4S3

437.52

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years